The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II pharmacokinetic and pharmacodynamic study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in patients with advanced pancreatic cancer receiving treatment with gemcitabine.
R. K. Ramanathan
Research Funding - Pharmacyclics
M. Chadha
No relevant relationships to disclose
V. Gressler
No relevant relationships to disclose
S. Shah
No relevant relationships to disclose
D. Loury
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
A. Hamdy
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
E. Hedrick
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
A. A. Khorana
Consultant or Advisory Role - Pharmacyclics
Honoraria - Pharmacyclics